It was intended for PET imaging of somatostatin receptor overexpression in adult patients with well-differentiated NETs excluding neuroblastomas
Αρχική World News EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide
It was intended for PET imaging of somatostatin receptor overexpression in adult patients with well-differentiated NETs excluding neuroblastomas